Bloom Harnesses Gut-Brain Axis To Develop ‘Bugs As Drugs’ For Rare Neurological Disease

02 Oct 2023

• By Ayisha Sharma

Gut Microbes Modulate Neuroinflammation And Neuroactive Molecules • Source: Shutterstock

Key Takeaways:

Bloom’s lead candidate, BL-001, comprises two microbes that replicate the antiepileptic effects of the ketogenic diet.

Bloom Science, Inc. is advancing a pipeline of live biotherapeutics derived from gut commensal microbes to alter key brain-gut microbiome interactions in a bid to treat rare neurological disorders.

The US firm was founded in 2018 by CEO Christopher Reyes, a biophysicist by training who started his entrepreneurial career...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Eolo Pharma Advances In Obesity With Thermogenesis Approach

04 Jul 2025

• By Aakash Babu

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

Immusoft Goes For Cell Therapy Plan ‘B’

26 Feb 2025

• By Alaric DeArment

Emerging Company Profile: CEO Sean Ainsworth spoke with Scrip about how the company is developing B-cell therapies to treat a range of diseases, starting with MPS I.

Sanofi-Backed Resalis Brings MicroRNA To Obesity

29 Nov 2024

• By Elizabeth Cairns

Emerging Company Profile: Resalis will soon start human trials of an oligonucleotide targeting a microRNA that is overexpressed in obese mice, but much remains to be proven in humans.

Volastra Aims To Terminate Cancer Relying On Chromosomal Instability

01 Nov 2024

• By Jessica Merrill

Emerging Company Profile: Volastra is testing two KIF18A inhibitors in early clinical trials in ovarian cancer, backed by investors like Polaris Partners and ARCH Ventures.

Dispatch Uses ‘Flare’ To Send CAR-Ts To Solid Tumors

23 Jul 2025

• By Alaric DeArment

With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.